A Phase II, Open Label, Parallel Group, Multi-center Study to Compare the Pharmacokinetics of Tacrolimus in Adult Subjects Undergoing Primary Allograft Transplantation Receiving an Advagraf or Prograf Based Immunosuppressive Regimen, Including a Long-term Follow-up.

Trial Profile

A Phase II, Open Label, Parallel Group, Multi-center Study to Compare the Pharmacokinetics of Tacrolimus in Adult Subjects Undergoing Primary Allograft Transplantation Receiving an Advagraf or Prograf Based Immunosuppressive Regimen, Including a Long-term Follow-up.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2014

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Heart transplant rejection; Kidney-pancreas transplant rejection; Lung transplant rejection; Pancreas transplant rejection
  • Focus Pharmacokinetics
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 22 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov. record.
    • 10 Jun 2013 Planned end date changed from 1 Jul 2016 to 1 Jul 2014 as reported by ClinicalTrials.gov.
    • 10 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top